These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 2556812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 6. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 8. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 9. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
    Abercrombie DM, Buchinski B, Salvato KA, Vovis GF, Stump DC, Broeze RJ.
    Thromb Haemost; 1990 Nov 30; 64(3):426-32. PubMed ID: 2128973
    [Abstract] [Full Text] [Related]

  • 10. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar 30; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 11. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis.
    Weitz JI, Kuint J, Leslie B, Hirsh J.
    Thromb Haemost; 1991 May 06; 65(5):541-4. PubMed ID: 1651568
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.
    de Munk GA, Groeneveld E, Rijken DC.
    Thromb Haemost; 1993 Sep 01; 70(3):481-5. PubMed ID: 8259553
    [Abstract] [Full Text] [Related]

  • 13. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A, Ling RJ, Sutton PM, Griffiths B, Riley PA, Atkinson T.
    Thromb Haemost; 1985 Apr 22; 53(2):200-3. PubMed ID: 4040659
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D.
    J Cell Biochem; 1987 Feb 22; 33(2):77-86. PubMed ID: 3553213
    [Abstract] [Full Text] [Related]

  • 15. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
    Stump DC, Stassen JM, Demarsin E, Collen D.
    Blood; 1987 Feb 22; 69(2):592-6. PubMed ID: 3099862
    [Abstract] [Full Text] [Related]

  • 16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 22; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 17. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    Thromb Haemost; 1988 Oct 31; 60(2):247-50. PubMed ID: 3146141
    [Abstract] [Full Text] [Related]

  • 18. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C, Lijnen HR, Van Hoef B, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):19-23. PubMed ID: 6495259
    [Abstract] [Full Text] [Related]

  • 19. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Aug 31; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 20. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR, De Wreede K, Demarsin E, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):31-3. PubMed ID: 6495261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.